📊 JRSS Key Takeaways
Is JRSIS HEALTH CARE Corp (JRSS) a Good Investment?
JRSS is technically insolvent with negative stockholders' equity of -$197.6K and critically depleted cash reserves of only $1.4K. Despite 101.4% revenue growth to $1.3M, the company burns -$826.1K in operating cash flow and -$1.1M in free cash flow annually, with an operating margin of -36.8% indicating unsustainable losses.
While revenue more than doubled year over year, losses remain substantial with negative operating and net margins and a deeply negative ROA. Negative shareholders’ equity, minimal cash, weak liquidity, and heavy cash burn create elevated going-concern risk without rapid margin improvement or external funding. Until the business demonstrates sustained margin expansion and positive operating cash flow, fundamentals remain unfavorable.
Why Buy JRSIS HEALTH CARE Corp Stock? JRSS Key Strengths
- Strong top-line revenue growth of 101.4% YoY demonstrates market traction
- Positive gross profit of $270.2K shows some operational contribution
- Active in healthcare services sector with operational presence
- Triple-digit YoY revenue growth (+101.4%)
- Low long-term debt balance
- Positive gross margin indicating some pricing power
JRSS Stock Risks: JRSIS HEALTH CARE Corp Investment Risks
- Negative stockholders' equity (-$197.6K) indicates technical insolvency and balance sheet deterioration
- Critically low liquidity: $1.4K cash with current ratio of 0.78x creates imminent solvency risk
- Massive operating losses (-$485.8K) and negative free cash flow (-$1.1M) indicate unsustainable cash burn
- Operating cash flow of -$826.1K and net margin of -33.0% show business model is unprofitable at scale
- No insider activity in past 90 days and liabilities exceed assets by $200K
- Negative equity, near-zero cash, and sub-1x liquidity signal acute financing risk
- Persistent operating losses and -80% FCF margin indicate unsustainable cash burn
- Negative interest coverage implies inability to service obligations without new capital
Key Metrics to Watch
- Monthly cash burn rate and cash runway (critical given $1.4K position)
- Operating cash flow trend (currently -$826.1K annually)
- Path to stockholders' equity recovery above zero
- Debt covenant compliance and refinancing risk
- Gross margin trend
- Operating cash flow
JRSIS HEALTH CARE Corp (JRSS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
JRSS Profit Margin, ROE & Profitability Analysis
JRSS vs Healthcare Sector: How JRSIS HEALTH CARE Corp Compares
How JRSIS HEALTH CARE Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is JRSIS HEALTH CARE Corp Stock Overvalued? JRSS Valuation Analysis 2026
Based on fundamental analysis, JRSIS HEALTH CARE Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
JRSIS HEALTH CARE Corp Balance Sheet: JRSS Debt, Cash & Liquidity
JRSS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: JRSIS HEALTH CARE Corp's revenue has grown significantly by 56% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
JRSS Revenue Growth, EPS Growth & YoY Performance
JRSS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $222.9K | -$26.9K | $0.00 |
| Q2 2024 | $337.4K | -$60.6K | $0.00 |
| Q1 2024 | $477.0K | $45.4K | $0.00 |
| Q3 2023 | $13.6K | -$119.1K | $-0.02 |
| Q2 2023 | $43.3K | -$105.0K | $-0.02 |
| Q1 2022 | $7.3M | $495.9K | $0.02 |
| Q3 2021 | $10.0M | $314.9K | $0.02 |
| Q2 2021 | $7.0M | $314.9K | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
JRSIS HEALTH CARE Corp Dividends, Buybacks & Capital Allocation
JRSS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for JRSIS HEALTH CARE Corp (CIK: 0001597892)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JRSS
What is the AI rating for JRSS?
JRSIS HEALTH CARE Corp (JRSS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JRSS's key strengths?
Claude: Strong top-line revenue growth of 101.4% YoY demonstrates market traction. Positive gross profit of $270.2K shows some operational contribution. ChatGPT: Triple-digit YoY revenue growth (+101.4%). Low long-term debt balance.
What are the risks of investing in JRSS?
Claude: Negative stockholders' equity (-$197.6K) indicates technical insolvency and balance sheet deterioration. Critically low liquidity: $1.4K cash with current ratio of 0.78x creates imminent solvency risk. ChatGPT: Negative equity, near-zero cash, and sub-1x liquidity signal acute financing risk. Persistent operating losses and -80% FCF margin indicate unsustainable cash burn.
What is JRSS's revenue and growth?
JRSIS HEALTH CARE Corp reported revenue of $1.3M.
Does JRSS pay dividends?
JRSIS HEALTH CARE Corp does not currently pay dividends.
Where can I find JRSS SEC filings?
Official SEC filings for JRSIS HEALTH CARE Corp (CIK: 0001597892) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JRSS's EPS?
JRSIS HEALTH CARE Corp has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JRSS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, JRSIS HEALTH CARE Corp has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JRSS stock overvalued or undervalued?
Valuation metrics for JRSS: ROE of N/A (sector avg: 15%), net margin of -33.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JRSS stock in 2026?
Our dual AI analysis gives JRSIS HEALTH CARE Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JRSS's free cash flow?
JRSIS HEALTH CARE Corp's operating cash flow is $-826.1K, with capital expenditures of $232.5K. FCF margin is -80.1%.
How does JRSS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -33.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.78 (avg: 2).